Pfizer Inc vs T1 Energy Inc. Common Stock — how do they compare? Pfizer Inc trades at $29.47 (market cap $161.70B), while T1 Energy Inc. Common Stock trades at $2.76 (market cap $868.55M). The key difference: Pfizer Inc is far larger — about 186.2× T1 Energy Inc. Common Stock's market cap, and Pfizer Inc pays a 6.06% dividend while T1 Energy Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and T1 Energy Inc. Common Stock for 0 Days on average.
| PFE | TE | |
|---|---|---|
Market Cap | $161.70B | $868.55M |
Volume | 26,828,084 | 19,771,934 |
Sector | Health | Industrials |
52-Week High | $29.21 | $12.04 |
52-Week Low | $23.67 | $2.72 |
Typical Hold Time | 158 Days | 0 Days |
Enterprise Value | $213.20B | $1.64B |
Dividend Yield | 6.06% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.37, down slightly by 0.11% on the day, with a bullish technical signal from moving averages. The company maintains strong profitability with a 73.18% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline developments, positioning for a catalyst-rich 2026.
Pfizer presents a mixed outlook with stable revenue around $63B but declining net income projections for 2026. The stock trades near analyst consensus target of $29.17, offering modest upside potential. Key risks include patent cliffs and competitive pressures, while the dividend yield and pipeline progress provide defensive appeal for income-focused investors.
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →